Bachem releases mobile app for their peptide partners

Bubendorf, Switzerland: – Peptide technology specialist Bachem AG has developed a smartphone and tablet application to help its customers manage their peptide needs on the move.

The Bachem app is now available for download from the App Store, Google Play and Microsoft for Windows 10.

Peptide game and calculator

The latest version 2.6 BACHEM App contains a host of features including product updates, company news, highlights, multimedia catalogs and brochures, a peptide calculator and even a peptide game to play on the move.

“Mobile apps like this represent the future for a customer-facing business like ours, achieving greater brand loyalty by creating new, faster and more attractive ways to access information on the move,“ said Stefan Andlauer, Bachem’s Director of Science & Relationship Marketing.

Popular demand

Bachem initially developed the app as a ‘highlight for visitors to its stand at CPhI 2015.

“The app proved so popular and well received, showing the high demand for mobile apps in our business, that we decided to extend the user group and make it public,” said Andlauer.

“It offers easy access from smartphone or tablet to a lot of useful information and literature including regular updates,” he noted.

Bachem created the app in partnership with German-based software developers XIDA Design and Technik.

About Bachem

The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.

Under its banner Pioneering Partner for Peptides, Bachem specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients (APIs). A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete its service portfolio.

Headquartered in Switzerland with subsidiaries in Germany, the UK, and the USA, the group specializes in process development and the manufacture of peptides and complex organic molecules as APIs as well as innovative biochemicals for research.

Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.

Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, new chemical entities (NCEs) and finished dosage forms at preclinical, clinical and production scales.

Resources

Click on BACHEM App to download the app.
Click on Bachems News to see latest News & Events.